Diamyd Medical AB: Advancing Diabetes Treatment through Biotechnology
Diamyd Medical AB, a prominent health care biotechnology company based in Stockholm, Sweden, continues to make strides in the treatment of autoimmune diabetes. The company, formerly known as Diamyd Therapeutics AB, is listed on the Swedish Stock Exchange and operates within the health care sector, specifically focusing on biotechnology.
As of May 29, 2025, Diamyd Medical AB’s close price stood at 8.88 SEK, with a market capitalization of 1.46 billion SEK. The company’s stock has experienced fluctuations over the past year, reaching a 52-week high of 20.15 SEK on August 11, 2024, and a low of 7.5 SEK on April 21, 2025. The price-to-earnings ratio is currently -6.43, reflecting the company’s ongoing investment in research and development.
Diamyd Medical AB is renowned for its innovative approach to diabetes treatment, particularly through its development of combination therapies. The company’s flagship product, Diamyd, is a Phase IIb clinical trial diabetes vaccine designed to treat autoimmune diabetes. This vaccine aims to modulate the immune system to prevent the destruction of insulin-producing beta cells in the pancreas.
In addition to Diamyd, the company is advancing Remygen, a regenerative and immunomodulatory therapy currently in phases Ib/IIa. Remygen targets both autoimmune and type 2 diabetes, offering a novel approach to managing these conditions by promoting the regeneration of beta cells and modulating the immune response.
Diamyd Medical AB’s commitment to innovation and its focus on addressing the unmet needs of diabetes patients position it as a key player in the biotechnology sector. As the company progresses through clinical trials and continues to develop its therapeutic pipeline, it remains at the forefront of efforts to transform diabetes treatment.
For more information on Diamyd Medical AB and its ongoing projects, stakeholders and interested parties can refer to the company’s official communications and updates on the Swedish Stock Exchange.